shivaani kummar ohsu email shivaani kummar ohsu email

In Brief. Notice of Privacy Practices Administrative Coordinator, Margaret Rogers For help with all referral needs and questions, visit Referring Physicians. OHSU is an equal opportunity affirmative action institution. CET membership is open to anyone at OHSU with an interest in advancing drug discovery and development. 2001-2022 Oregon Health & Science University. Dr. Shivaani Kummar, MD is a medical oncology specialist in Portland, OR. Together their goal is to find a cure for cancer. Each faculty member comes with a unique background, which often propels him or her into medicine and a particular . Shivaani Kummar: STUDY00021194: A phase 1 study of SGN-CD228A in select advanced solid tumors: . Shivaani Kummar Director of Center for Experimental Therapeutics, Professor and Endowed Chair, Knight Cancer Institute She currently practices at Oregon Health And Sciencs University Primary Care Clinic and is affiliated with Stanford Health Care. OHSU is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. February 17, 2023. The 13,000-square-foot early-phase research unit is located on the 12th floor of OHSUs Center for Health and Healing Building 2 on OHSUs South Waterfront campus. billing andinsurancesection of our site, Medical Oncology and Hematology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, American Board of Internal Medicine Board Certified in Internal Medicine, 1995-2005, Board Recertified in Internal Medicine, 2005-2015, Board Certified in Medical Oncology, 1998-2008, Board Recertified in Medical Oncology, 2008-2018; 2018-2028 Board Certified in Hematology, 2002-2012, Member, American Society of Clinical Oncology, Member, American Association for Cancer Research. . (OHSU/Joe Rojas-Burke), The new unit centralizes care for patients in research studies and expands capacity to allow more people to participate in early-phase clinical trials at OHSU. 2001-2023 OHSU. This trial will study tisotumab vedotin to find out whether it is an effective treatment for certain solid tumors and what side effects (unwanted effects) may occur. The purpose of the study is to learn more about the study drug, VIP152, in combination with pembrolizumab in people with advanced or . Shivaani Kummar (Principal Investigator, PI). OHSU 'Mary Crowley Cancer Research', 'Montefiore Medical Center' 4 1 . This new unit allows us to centralize everything in a setting designed for a patients convenience and comfort, said Patrick McCormick, M.B.A., vice president of oncology services in the Knight Cancer Institute. This symposium is intended to be an annual event that rotates its location between Stanford University, the University of Chicago, the University of Connecticut and the Oregon Health Science University. What excites you about coming to work in the morning? Dr. Shivaani Kummar has primarily specialised in Medical Oncology for over 31 years. Articles Cited by Public access. However, high costs, long development t Dr. Kummar joined the OHSU Knight Cancer Institute from Stanford University in July 2020. Shivaani Kummar, Lisa Coussens named deputy directors of OHSU Knight Shivaani KummarLisa CoussensShivaani Kummar and Lisa Coussens were named deputy directors of OHSU Knight Cancer Institute. Give Now. ( ) (MCI) 'BAL0891' 1 27 . 5 , IND transfer 4 . 23() 'Oregon Health . Shivaani Kummar (Principal Investigator, PI), OHSU Mary Crowley Cancer Research, Montefiore Medical Center 4 1 . 2001-2023 OHSU. Overall: 4.7 out of 5 To find better ways to treat patients. A Drilon, TW Laetsch, S Kummar, SG DuBois, UN Lassen, GD Demetri, New England Journal of Medicine 378 (8), 731-739. They say they shared an interest in cancer drug discovery and development that grew after their marriage. Home; NPI Lookup; Doctors; Medical Groups & Orgs; Taxonomy Codes; Lookup NPI Numbers from the NPI Registry . February 17, 2023 In Brief Edith Mitchell named enterprise vice president for cancer disparities at Jefferson SKCC Shivaani Kummar, MD, FACP, is head of the Division of Hematology and Medical Oncology in the OHSU School of Medicine, associate director for Clinical and Translational Research at the OHSU Knight Cancer Institute, and co-director of the Knight Cancer Institute's Center for Experimental Therapeutics. Due to Covid-19 pandemic, the 2020 Symposium was postponed to 2021. Early-phase trials are the first step in testing promising new medications and methods, and can offer patients early access to new and possibly better treatments. The patient ratings score is an average of all responses to the question "How likely would you be to recommend this provider to your family and friends (on a scale of 0 to 10)" on our nationally-recognized NRC patient surveys. Shivaani Kummar. Seventeen patients with desmoid tumors received PF-03084014 150 mg orally twice a day in 3-week cycles. massachusetts vs washington state. S Kummar, J Ji, R Morgan, HJ Lenz, SL Puhalla, CP Belani, DR Gandara, Clinical Cancer Research 18 (6), 1726-1734. bard college music faculty. She shares our urgency to better understand how research and drug development can help the patients who desperately need better treatments, today.. If you made any changes in Pure these will be visible here soon. 2001-2022 Oregon Health & Science University. OHSU is an equal opportunity affirmative action institution. If you proceed in scheduling an appointment and your healthinsurancebenefits do not participate with OHSU providers, your out of pocket liability may be higher. When were developing new treatments for cancer, we are often trying to identify what makes the cancer different from normal cells or why currently used drugs are not working as well as we would like them to. boundtree continuing education; can you be charged under ucmj after discharge Try restaurant style recipes at home. Faculty and staff recruitment information. Shivaani Kummar, M.D., will lead the Division of Hematology and Medical Oncology in the OHSU School of Medicine, overseeing more than 90 faculty members. Box 29017 Portland, OR 97296, Portland Office 2020 SW 4th Avenue Suite 900 Portland, OR 97201. In 2021, we held our 4th Stat4Onc Symposium virtually by Stanford University. Affiliated Hospitals Medical Group Practices Practice Location 3181 Sw Sam Jackson Park Rd Portland, Oregon 97239-3011 Map and Directions Phone: (503) 314-7168 Office Hours: Monday - Friday: 8:00 AM - 5:00 PM Saturday - Sunday: Closed Each study answers scientific questions and tries to find better ways to prevent, diagnose or treat diseases like cancer. what was bolivar's ultimate goal? S Kummar, ME Gutierrez, ER Gardner, X Chen, WD Figg, M Zajac-Kaye, European journal of cancer 46 (2), 340-347, Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials, Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies, Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and LymphomasPhase I Trial of ABT-888 with Topotecan, Phase I study of single-agent AZD1775 (MK-1775), a Wee1 kinase inhibitor, in patients with refractory solid tumors, Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements, Compressing drug development timelines in oncology using phase'0'trials, Wee1 kinase as a target for cancer therapy, Using cereal grain winter cover crops to reduce groundwater nitrate contamination in the mid-Atlantic coastal plain, A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas, SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter StudySD-101 Combined with Pembrolizumab in Advanced Melanoma, Cediranib for metastatic alveolar soft part sarcoma, Primary non-Hodgkin's lymphoma of the liver, Drug development in oncology: classical cytotoxics and molecularly targeted agents, A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid TumorsPhase I Study of Olaparib with Cisplatin and Gemcitabine, Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell CancerAdenosine 2A Receptor Blockade as a Cancer Immunotherapy, Advances in using PARP inhibitors to treat cancer, Clinicopathologic Features of NonSmall-Cell Lung Cancer Harboring an, Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies, Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. (Getty Images), Communications Manager, OHSU Knight Cancer Institute, Husband-wife team from Stanford University tapped to lead two cancer programs at OHSU, OHSU leading effort to make cancer trials more inclusive, Making Hepatitis C care easier when treatment seems impossible, Pill for skin disease also curbs excessive drinking, OHSU clinical trial tests exercise for multiple sclerosis treatment. Notice of Privacy Practices Expanding scientific knowledge is a key mission of OHSU, Oregons only academic health center. Administrative Coordinator, Denise Hopkins Dr. Drukers vision for the field of translational oncology is similar to our vision of how to move discoveries from laboratories towardthe clinic. Accueil; Solution; Tarif; PRO; Mon compte; France; Accueil; Solution Oregon Health & Science University is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. OHSU is an equal opportunity affirmative action institution. Shivaani KummarLisa CoussensShivaani Kummar and Lisa Coussens were named deputy directors of OHSU Knight Cancer Institute . Recent external collaboration on country/territory level. Our ability to collaborate with academics and industries across the globe will be paramount to our success in developing new drugs for patients. The institute is involved with more than 400 clinical trials, including 113 early-phase trials. Claire Yoshida, M.S.N., A.C.N.S.-B.C., A.C.H.P.N. We are proud to be able to offer our patients access to the most advanced cancer therapies available, said Shivaani Kummar, M.D., FACP, head of the Division of Hematology and Medical Oncology in the OHSU School of Medicine and co-director of the Knight Cancer Institutes Center for Experimental Therapeutics. Support the Abortion Care and Training Fund. She accepts multiple insurance plans. Accepting new patients Equipment. Over the past six months, a multidisciplinary team has been coordinating patient experience, drug delivery, staffing schedules and equipment needed to support the range of clinical trials offered in the unit that span 14 different cancer disease groups. Response to treatment was evaluated at cycle 1 and every six cycles, that is, 18 weeks, by RECIST (Response Evaluation Criteria in Solid Tumors) version 1.1. Leadership The Center for Experimental Therapeutics is co-led by Sanjay Malhotra, Ph.D., and Shivaani Kummar, M.D. Recent progress in understanding the molecular basis of cellular processes, identification of promising therapeutic targets and evolution of the regulatory landscape makes this an exciting and unprecedented time to be in the field of oncology drug development. scripps institution of oceanography graduate programs; rosemont seneca advisors website Increasing patient participation in oncology clinical trials, A Novel Artificial IntelligencePowered Method for Prediction of Early Recurrence of Prostate Cancer after Prostatectomy and Cancer Drivers, Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas, Comparative Effectiveness of Larotrectinib and Entrectinib for TRK Fusion Cancer. What sort of projects are you working on right now? Administrative Coordinator, Felicia Feingersch Then we try to find what we call targets within or around cancer cells and develop drugs that can precisely hit those targets. A husband-wife team known for specializing in cancer drug development have joined the OHSU Knight Cancer Institute. SHIVAANI KUMMAR, 207RX0202X - Medical Oncology Doctors & Physicians in PORTLAND, OR. Stock and Other Ownership Interests: PathomIQ, Arxeon Therapeutics (I) Consulting or Advisory Role: Seattle Genetics, Bayer, Boehringer Ingelheim, Mundipharma EDO GmbH, Harbour BioMed, SpringWorks Therapeutics, Gilead Sciences, Mirati Therapeutics, EcoR1 Capital, Cadila Pharmaceuticals (I), Oxford BioTherapeutics. A Ribas, T Medina, S Kummar, A Amin, A Kalbasi, JJ Drabick, M Barve, S Kummar, D Allen, A Monks, EC Polley, CD Hose, SP Ivy, IB Turkbey, Journal of Clinical Oncology 31 (18), 2296, Critical reviews in oncology/hematology 53 (3), 199-207, S Kummar, M Gutierrez, JH Doroshow, AJ Murgo, British journal of clinical pharmacology 62 (1), 15-26. Will you join us. Shivaani Kummar, M.D., FACP, head of the Division of Hematology and Medical Oncology in the OHSU School of Medicine and co-director of the Knight Cancer Institute's You can also correspond with Dr. Shivaani Kummar through mail at her mailing address at 3181 Sw Sam Jackson Park Rd, , Portland, Oregon - 97239-3011 (mailing address contact number . The unit includes 12 treatment spaces, eight chairs, four beds, and procedure and consultation rooms. Her husband is a synthetic medicinal chemist who leads the Center for Experimental Therapeutics dedicated to discovery new cancer treatments. OHSU HOSPITAL AND CLINICS - (Acute Care) 3181 SW SAM JACKSON PARK ROAD Education & Training Oregon Health & Science University Fellowship, Hematology and Medical Oncology, 1995 - 1997 New York Presbyterian Hospital (Columbia Campus) Residency, Internal Medicine, 1990 - 1993 Harvard Medical School Class of 1989 By using this website, we will assume that you agree to the terms and conditions of our privacy policy. The Knight Cancer Institutes Center for Experimental Therapeutics (CET) represents multidisciplinary collaborations among scientists, physicians and engineers across OHSU. A husband-wife team known for specializing in cancer drug development have joined the OHSU Knight Cancer Institute. Most recently, he was the director for Stanford SRI Drug Discovery and Development Program, and he trained with Nobel laureate Herb Brown at Purdue University. 1. cleveland, tx funeral homes share dancing on ice app for ipad tweet exhaustive list of cushing's syndrome symptoms share. You may also qualify for Phase 1 Program trials. (h.c.), Ph.D., FAACR. Oregon Health & Science University is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. PHYSICIAN HELPLINE Phone: 1-866-742-4811 Fax: 650-320-9443 Monday - Friday, 8 a.m. - 5 p.m. Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. Shivaani Kummar Dr. Kummar was recently appointed as Division Chief of Hematology and Oncology, and co-Director of the Center for Experimental Therapeutics, at the Oregon Health and Science University in Portland, Oregon. I am humbled and inspired by the courage, grace and feeling of altruism that I find in each and every patient who chooses to participate in these trials. Read more to learn about Shivaani Kummar, MBBS's background, education, and other specialties. (OHSU/Kristyna Wentz-Graff). Sign up to receive the latest news, updates and stories from the OHSU Foundation in your inbox. OHSU is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. Uncategorized . BAL0891 . Keep me signed in. edu h-index 8546 Citations 49 h-index 1996 2023 Research activity per year Overview Fingerprint Network Grants (5) Publications (174) Similar Profiles (1) If you made any changes in Pure these will be visible here soon. 2001-2022 Oregon Health & Science University. Shivaani Kummar, M.D., FACP Lisa M. Coussens, M.D. Shivaani Kummar, M.D., will lead the Division of Hematology and Medical Oncology in the OHSU School of Medicine, overseeing more than 90 faculty members. lions led by donkeys for and against. Dr. Dr. Kummar is a cancer specialist whose focus is to bring new discoveries to the clinic, developing new treatments for cancer. OHSU is an equal opportunity affirmative action institution. Shivaani Kummar. Cancer Early Detection Advanced Research Center, Adolescent and Young Adult Oncology Program, Social and Emotional Side Effects of Cancer, International Alliance for Early Cancer Detection (ACED), Lisa M. Coussens, M.D. condition, procedure, doctor name. Shivaani Kummar (OHSU) kummar@ohsu.edu Upon completing her medical degree from Lady Hardinge Medical College in New Delhi, India, Shivaani Kummar moved to the United States to train in Internal Medicine at Emory University in Atlanta, Georgia. Learn more about clinical trials at the Knight Cancer Institute, The 13,000-square-foot early-phase research unit includes 12 treatment spaces, eight chairs, four beds, and procedure and consultation rooms. She also leads the division of hematology & medical oncology in the OHSU School of Medicine. Kummar and Malhotra who have a high school-aged daughter and middle school-aged son met while she was faculty at Yale University. Under his leadership, the Knight Cancer Institute is actively engaged in doing so., Brian Druker, M.D., Knight Cancer Institute director, JELD-WEN Chair of Leukemia Research; investigator, Howard Hughes Medical Institute. The new early-phase research unit completes this expansion in the building. Shivaani Kummar Stanford University Medical Center - PMWC Precision Medicine World Conference Speaker Profile M.D., Professor of Medicine and Radiology, Stanford University; Director, Phase I Clinical Research Program-Medical Oncology; Director, Translational Oncology Program At Stanford Shivaani Kummar Biography Dr. Oregon Health & Science University is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. Trisha Silbernagel, RN, BSN, early-phase clinical trial unit manager, checks equipment on Aug. 23, 2021. Our patients in research studies can come in for their initial blood work and continue through their post treatment observation all in one place and are surrounded by a team of experts guiding them through the process.. 2001-2023 OHSU. Only fill in if you are not human. Email: trials@ohsu.edu Call: 503-494-1080 Oregon Health & Science University. Web Browser Accessibility, A PHASE 1/2 DOSE ESCALATION AND DOSE EXPANSION STUDY OF MECBOTAMAB VEDOTIN (BA3011) ALONE AND IN COMBINATION WITH NIVOLUMAB IN ADULT AND ADOLESCENT PATIENTS 12 YEARS AND OLDER WITH ADVANCED SOLID TUMORS, A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor, A Phase 1a/b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination with Anticancer Therapies in Subjects with Solid Malignancies, A double-blind, placebo-controlled, randomized, dose-escalating, multicenter, Phase 1 study to assess the safety and tolerability of ART-123 in combination with leucovorin/5-fluorouracil/oxaliplatin and bevacizumab in metastatic colorectal cancer patients, A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion Study of Intravenously Administered 23ME-00610 in Patients with Advanced Solid Malignancies, A PHASE 1 STUDY OF KSQ-4279 ALONE AND IN COMBINATION IN PATIENTS WITH ADVANCED SOLID TUMORS. Spray Foam Equipment and Chemicals. Shivaani Kummar, M.D., will lead the Division of Hematology and Medical Oncology in the OHSU School of Medicine, overseeing more than 90 faculty members. In her most recent role at Stanford University, Kummar held a number of titles, including: professor of medicine and radiology; associate division chief for academic affairs; director, phase I clinical research program; and co-director of the Translational Oncology Program. Username or E-mail. Web Browser Accessibility, New early-phase clinical trial unit in the Center for Health and Healing Building 2 on South Waterfront centralizes care for cancer patients, provides more research opportunities, OHSU expands capacity for cancer clinical trials, OHSU Knight Cancer Institute: Understanding Cancer Clinical Trials, Expanding access to experimental cancer treatments in Oregon: Q&A with Shivaani Kummar, Severe respiratory illness season means boom times for OHSU virtual immediate care, OHSU leading effort to make cancer trials more inclusive, OHSU Child Life Specialist provides life-changing care to young patient living with chronic spinal condition, Making Hepatitis C care easier when treatment seems impossible. These new agents include those targeting genetic changes (alterations in the DNA of the cancer cell), those that harness the immune system to work against the cancer, and others. 2001-2022 Oregon Health & Science University. We have a number of clinical trials investigating promising new strategies to treat cancer. Dr. OHSU is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. . OHSU is an equal opportunity affirmative action institution. Caring for them drives me to work harder to develop more effective treatments that are better tolerated. In 2014, the state of Oregon supported the OHSU Knight Cancer Challenge by providing $200 million in bonding to support building cancer research and clinical trial capacity. Notice of Privacy Practices OHSU Knight Cancer Institute leaders include some of the most distinguished doctors and scientists in the world. Dr. Kummar loves to spend time with her family, read, and go for long walks. Division head of medical oncology Shivaani Kummar, M.D., FACP Accepting new patients Division head of radiation medicine Arthur Y. Get to know some of the resear. Charles D. Blanke, M.D., F.A.C.P., F.A.S.C.O. Shivaani Kummar: STUDY00021766: . The OHSU Knight Cancer Institute has expanded its cancer research and care facilities to include a unit dedicated to serving patients participating in early-phase clinical trials. These topic labels come from the works of this person. (h.c.), Ph.D., FAACR Director of CEDAR Sadik Esener, Ph.D. Director of precision oncology and SMMART Gordon Mills, M.D.,Ph.D. Patients and Methods. The new unit centralizes care for patients in research studies and expands capacity to allow more people to participate in early-phase clinical trials at OHSU. Their partnership will be a perfect pairing.. The Division of Hematology and Medical Oncology is headed by Shivaani Kummar, M.D., FACP and composed of many sections: Classical Hematology Community Oncology Hematologic Malignancies Palliative Care Portland VA Research Solid Tumor Stem Cell Transplantation Administration Section head Shivaani Kummar, M.D., FACP Of that, $160 million was used for the Knight Cancer Research Building, which opened in 2018, and $40 million was used to build expanded capacity for clinical trial care in CHH2, which opened in 2019. Share on print. Select a country/territory to view shared publications and projects. 9842741222, 9942641222, 9842724434 chinamanpaversscc@gmail.com. The Knight Cancer Institute's Center for Experimental Therapeutics (CET) represents multidisciplinary collaborations among scientists, physicians and engineers across OHSU. OHSU Knight Cancer Institute is a national leader in cancer research and training and well-known for its ability to turn cancer research discoveries into new cancer treatments. The Division of Hematology and Medical Oncology is headed byShivaani Kummar, M.D., FACPand composed of many sections: Kathleen Beebe Shivaani Kummar, M.D., FACP, is head of the Division of Hematology and Medical Oncology in the OHSU School of Medicine and co-director of the Knight Cancer Institute's Center for Experimental Therapeutics. Email: trials@ohsu.edu Call: 503-494-1080 Oregon Health & Science University. Privacy Notice: We use technologies, such as cookies, to customize content and advertising, to analyze traffic to the site and to provide a better overall experience to our users. Clinical trials are research studies that test how well new medicines or treatments work in people. Verified email at ohsu.edu. The provider's speciality is Internal Medicine with a focus in Medical Oncology How many years of experience does Dr. Shivaani Kummar have? The field of oncology is so broad, and theres so much to be done, Kummar says. He has the mindset and the clear vision to make that mindset a reality., Malhotra agrees: We speak the same language. Dive into details by clicking on the dots or, Knight Cancer Translational Oncology Program, Calculated based on number of publications stored in Pure and citations from Scopus, PQ3: Age-related immune deviation and cancer outcome, [18F]-AraG -PET imaging to evaluate immunological response to checkpoint inhibitor therapy (CKI) in patients with advanced solid tumors, Understanding the origins of rapid recurrence of pancreatic cancer after resection. The two will co-lead the institutes new Center for Experimental Therapeutics, uniting cutting-edge technologies with multidisciplinary preclinical and clinical investigators. Shivaani Kummar: STUDY00022986: An open-label, multicenter Phase I dose escalation study to characterize safety, tolerability, preliminary antitumor activity, pharmacokinetics and maximum tolerated dose of VIP152 (BAY 1251152) as monotherapy or combination therapy in subjects with advanced cancer . This conversation is with Shivaani Kummar, MD (professor, oncology), who joined the Stanford faculty in January 2015. Shivaani Kummar 1 2 , Apurva K Srivastava 3 , Tony Navas 3 4 , Fabiola Cecchi 5 6 , Young H Lee 5 7 , Donald P Bottaro 5 , Sook Ryun Park 1 8 , Khanh T Do 1 9 , Woondong Jeong 1 10 , Barry C Johnson 1 , Andrea R Voth 1 , Larry Rubinstein 11 , John J Wright 1 , Ralph E Parchment 3 , James H Doroshow 1 12 , Alice P Chen 13 OHSU Foundation P.O. L Fong, A Hotson, JD Powderly, M Sznol, RS Heist, TK Choueiri, S Kummar, A Chen, RE Parchment, RJ Kinders, J Ji, JE Tomaszewski, AF Farago, MS Taylor, RC Doebele, VW Zhu, S Kummar, AI Spira, S Kummar, M Gutierrez, ER Gardner, E Donovan, K Hwang, EJ Chung, Clinical Cancer Research 13 (18), 5411-5417. Our new center will foster collaboration across disciplines, bringing together investigators interested in developing new treatments, Malhotra says. A Rajan, CA Carter, RJ Kelly, M Gutierrez, S Kummar, E Szabo, Clinical cancer research 18 (8), 2344-2351. Dr. Shivaani Kummar is an oncologist in Palo Alto, California and is affiliated with OHSU Hospital. OHSU researchers lead innovation and passion through new discoveries, comradery of the OHSU research community and the drive to improve peoples health and well-being. My clinical work is focused on conducting early phase clinical trials, enrolling and caring for patients on these trials. In addition to her role as division head, Kummar will serve as co-director for a new center in the Knight Cancer Institute, theCenter for Experimental Therapeutics, which she will co-lead with Sanjay Malhotra, Ph.D. Kummar brings a wealth of experience in conducting clinical trials tailored to make early, informed decisions regarding the suitability of new drug candidates for further clinical investigation. 1 - 20 out of 67 Results for "Shivaani Kummar" 67 Results Select All . Updated health-related quality of life of patients with TRK-fusion cancer treated with larotrectinib in clinical trials. Dr. Kummar specializes in the care and treatment of patients with cancer. All these new agents have shown promising anticancer activity in laboratory testing and are now being evaluated in patients. Across OHSU, doctors and researchers are reimagining early disease detection. Local: (503) 228-1730 | Toll Free: (800) 462-6608 Cited by. Notice of Privacy Practices shivaani kummar ohsu email. Her research interests focus on developing novel therapies for cancer. Malhotras background is in chemical biology and drug development with a strong expertise in medicinal chemistry, including small molecule synthesis. Drukers approach to team science is incorporated throughout the institutes infrastructure. Shivaani Kummar is a Hematology & Medical Oncology Head at Oregon Health & Science University based in Portland, Oregon. Together they form a unique fingerprint. February 17, 2023. Primary Care Physicians Browse Primary Care Physiciansnear you Atlanta, GA Austin, TX Baltimore, MD Boston, MA Chicago, IL Dallas, TX Denver, CO Detroit, MI Houston, TX